Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efimosfermin versus placebo in compensated cirrhosis due to MASH
NL-OMON61721Phase 3Not yet recruiting
- Sponsor
- GSK
- Start
- Nov 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing Efimosfermin alfa with Placebo (2 arms). Primary endpoint: Time to adjudicated composite liver-related clinical outcome. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
efimosfermin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NL-OMON61721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61721.